Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954069 | 0.95 | SMN1; SMN2 (0.58) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL4055307 | 0.94 | SMN1; SMN2 (0.57) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL3956731 | 0.94 | SMN1; SMN2 (0.57) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL3953652 | 0.93 | MEN1 (0.59) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL3953445 | 0.92 | ALDH1A1 (0.58) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL3953292 | 0.92 | MEN1 (0.74) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL4541507 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL8360044 | 0.89 | GAA (0.55) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL8363155 | 0.83 | MAPK1 (0.53) | SMN1; SMN2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL8363238 | 0.83 | MAPK1 (0.59) | SMN1; SMN2MEN1KMT2AGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551388-A4 | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH | SIGNAL PHARM INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20060142352-A1 | Compounds useful for the treatment of cancer, compositions thereof and methods therewith | SIGNAL PHARMACEUTICALS, LLC | 2006-06-29 | — | — | US | disclosed |
| US-7037936-B2 | Compounds useful for the treatment of cancer, compositions thereof and methods therewith | SIGNAL PHARMACEUTICALS, LLC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060030617-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH | NEW YORK UNIVERSITY | 2006-02-09 | — | — | US | disclosed |
| CN-1674888-A | Compounds for the treatment of cancer, compositions thereof and methods of use thereof | SIGNAL PHARM INC (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1551388-A2 | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH | Signal Pharmaceuticals, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2003105774-A2 | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142352-A1 | Compounds useful for the treatment of cancer, compositions thereof and methods therewith | KEAP1, VHL, IKBKG | SMN1; SMN2 2919/4885MEN1 2685/4885KMT2A 585/4885 |
| US-20060030617-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH | KEAP1, VHL, IKBKG | SMN1; SMN2 2919/4885MEN1 2685/4885KMT2A 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.